Abobotulinumtoxina
Dysport (abobotulinumtoxina) is an unknown pharmaceutical. Abobotulinumtoxina was first approved as Dysport on 2009-04-29. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and hyperhidrosis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Dysport
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dysport | Biologic Licensing Application | 2024-10-24 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
abobotulinumtoxina, Dysport, Ipsen Biopharm Limited | |||
| 2123-07-29 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0586 | Injection, abobotulinumtoxina, 5 units |
Clinical
Clinical Trials
1195 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle spasticity | D009128 | HP_0001257 | — | 8 | 17 | 44 | 25 | 64 | 151 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 8 | 17 | 25 | 28 | 33 | 105 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 5 | 11 | 28 | 15 | 31 | 85 |
| Cerebral palsy | D002547 | — | G80 | 3 | 10 | 21 | 6 | 27 | 63 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 3 | 9 | 15 | 14 | 21 | 59 |
| Torticollis | D014103 | HP_0000473 | F45.8 | 5 | 12 | 12 | 11 | 18 | 56 |
| Dystonia | D004421 | HP_0001332 | G24 | 5 | 11 | 13 | 10 | 21 | 56 |
| Syndrome | D013577 | — | — | 12 | 22 | 9 | 4 | 10 | 50 |
| Dystonic disorders | D020821 | — | G24 | 5 | 10 | 13 | 9 | 16 | 49 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 4 | 7 | 15 | 12 | 10 | 44 |
Show 139 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 5 | 8 | — | 2 | 12 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 4 | 5 | — | 2 | 10 |
| Equinus deformity | D004863 | — | — | — | 1 | 1 | — | 8 | 10 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | 6 | 2 | — | 2 | 9 |
| Fasciitis | D005208 | HP_0100537 | M72.9 | 1 | 6 | 2 | — | 2 | 9 |
| Talipes | D000070558 | HP_0001883 | Q66.1 | — | 1 | 1 | — | 7 | 9 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | 1 | 2 | 1 | — | 4 | 8 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | 5 | 2 | — | 1 | 8 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 4 | 1 | — | 2 | 7 |
| Ganglion cysts | D045888 | — | M67.4 | 2 | 4 | 2 | — | 1 | 7 |
Show 70 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle cramp | D009120 | HP_0003394 | — | 1 | 3 | — | — | 2 | 5 |
| Contracture | D003286 | HP_0001371 | M62.4 | — | 2 | — | — | 3 | 5 |
| Myalgia | D063806 | HP_0003326 | M79.1 | — | 1 | — | — | 2 | 3 |
| Abdominal hernia | D046449 | — | K46 | — | 1 | — | — | 2 | 3 |
| Internal hernia | D000082122 | — | — | — | 1 | — | — | 2 | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | 2 | 3 |
| Neck pain | D019547 | HP_0030833 | M54.2 | 2 | 1 | — | — | 1 | 3 |
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | — | 3 | — | — | — | 3 |
| Ventral hernia | D006555 | EFO_1001866 | K43 | — | 1 | — | — | 1 | 2 |
| Pancreatic fistula | D010185 | — | — | — | 1 | — | — | 1 | 2 |
Show 68 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic stroke | D000083302 | — | — | 1 | — | — | — | 2 | 3 |
| Complex regional pain syndromes | D020918 | EFO_1001998 | — | 1 | — | — | — | 2 | 3 |
| Reflex sympathetic dystrophy | D012019 | EFO_1001147 | G90.5 | 1 | — | — | — | 2 | 3 |
| Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | 1 | — | — | — | 1 | 2 |
| Skin abnormalities | D012868 | HP_0000951 | Q82.9 | 1 | — | — | — | 1 | 2 |
| Intracranial sinus thrombosis | D012851 | — | — | 1 | — | — | — | — | 1 |
| Internal carotid artery dissection | D020215 | — | — | 1 | — | — | — | — | 1 |
| Vertebral artery dissection | D020217 | — | I77.74 | 1 | — | — | — | — | 1 |
| Vascular headaches | D014653 | — | — | 1 | — | — | — | — | 1 |
| Bursitis | D002062 | EFO_1000941 | M71.9 | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
| Flushing | D005483 | — | R23.2 | — | — | — | — | 2 | 2 |
| Pancreatectomy | D010180 | EFO_0002581 | — | — | — | — | — | 1 | 1 |
| Treatment outcome | D016896 | — | — | — | — | — | — | 1 | 1 |
| Muscle tonus | D009129 | — | — | — | — | — | — | 1 | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
| Physical therapy modalities | D026741 | — | — | — | — | — | — | 1 | 1 |
| Anticholinergic syndrome | D064807 | — | — | — | — | — | — | 1 | 1 |
| Erythema | D004890 | HP_0010783 | L53.9 | — | — | — | — | 1 | 1 |
| Intravesical administration | D000283 | — | — | — | — | — | — | 1 | 1 |
Show 44 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abobotulinumtoxina |
| INN | — |
| Description | Botulinum toxin, or botulinum neurotoxin (commonly called botox), is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.
|
| Classification | Neurotoxin |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >2VU9:A|BOTULINUM NEUROTOXIN A HEAVY CHAIN
MGSSHHHHHHSSGLVPRGSHMDTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIV
YNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINR
WIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSN
SGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNI
VRNNDRVYINVVVKNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFH
QFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPLQ |
Identifiers
| PDB | 2G7P, 2VU9, 2VUA, 3BTA, 3DDA, 3DDB, 3DS9, 3DSE, 3FUO, 3K3Q, 3QIX, 3QIY, 3QIZ, 3QJ0, 3QW5, 3QW6, 3QW7, 3QW8, 3ZUR, 3ZUS, 4EJ5, 4EL4, 4ELC, 4HEV, 4IQP, 4JRA, 4KS6, 4KTX, 4KUF, 4ZJX, 5JLV, 5JMC, 5L21, 5MK6, 5MK7, 5MOY, 5TPB, 5TPC, 5V8P, 5V8R, 5V8U, 5VGV, 5VGX, 6DKK, 6ES1, 6MHJ, 6XCB, 6XCC, 6XCD, 6XCE, 6XCF, 7N18 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108570 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,881 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dysport
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,159 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use